Trametinib, a MEK 1/2 inhibitor, was FDA approved as a single agent (2013) and in combination with the BRAF inhibitor, dabrafenib (2014), for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations [53,54]. Here, BRAF is linked to metastatic melanoma.